These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22419099)

  • 1. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
    Tsutsumi Y; Ogasawara R; Miyashita N; Tanaka J; Asaka M; Imamura M
    Int J Hematol; 2012 May; 95(5):588-91. PubMed ID: 22419099
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
    Brugger W; Ghielmini M
    Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Rummel MJ; Mitrou PS; Hoelzer D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryoglobulins mimicking platelet recovery in a mantle cell lymphoma patient treated with chemoimmunotherapy.
    Herishanu Y; Katz BZ
    Blood; 2015 Feb; 125(6):1047. PubMed ID: 25802907
    [No Abstract]   [Full Text] [Related]  

  • 7. The emerging role of bendamustine in follicular lymphoma.
    Friedberg JW
    Leuk Lymphoma; 2009 Mar; 50(3):317-8. PubMed ID: 19347722
    [No Abstract]   [Full Text] [Related]  

  • 8. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma.
    Koo YX; Tan DS; Tan IB; Tao M; Lim ST
    Ann Intern Med; 2009 May; 150(9):655-6. PubMed ID: 19414854
    [No Abstract]   [Full Text] [Related]  

  • 10. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Garnock-Jones KP
    Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of granuloma annulare following treatment with bendamustine and rituximab in a patient with follicular lymphoma: a serendipitous finding.
    Shah BK; Hewett Y; Peterson A; Tretheway D
    J Postgrad Med; 2014; 60(4):406-8. PubMed ID: 25370553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
    Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
    Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
    Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
    Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
    [No Abstract]   [Full Text] [Related]  

  • 16. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.
    Gueli A; Gottardi D; Hu H; Ricca I; De Crescenzo A; Tarella C
    Blood Transfus; 2013 Apr; 11(2):311-4. PubMed ID: 23399352
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
    Hui M; Chen M
    Ann Hematol; 2022 Apr; 101(4):911-913. PubMed ID: 34487230
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
    Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.